$6.8M Investment Pushes Pronota Closer To Development of Diagnostics Pipeline | GenomeWeb

This story originally ran on July 8.

By Tony Fong

Belgian protein biomarker firm Pronota has completed the first close of its Series B financing, raising €4.9 million ($6.8 million) that it will use to advance its diagnostics development programs.

The company announced the close last week, and in an interview with ProteoMonitor, CEO Nick McCooke said that the second close on the financing round with a target goal of €5 million is expected before the end of the year.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Cell this week: phosphoproteomic patterns in prostate cancer, effect of gene expression on fitness in yeast, and more.

Scripps Research Institute investigators peer back at the RNA world.

Being born premature shouldn't mean infants with high blood sugar levels don't undergo genetic testing for neonatal diabetes, a study in Pediatrics says.

In PNAS this week: chromosome instability in S. cerevisiae, structural differences and sequence divergence in rice, and more.